第二代雄激素受体抑制剂在晚期前列腺癌的研究新进展

打开文本图片集

Advances in second-generation androgen receptor inhibitors for advanced prostati cancer

WANG Baojun，XU Junnan，NIU Shaoxi，LI Zhuoran，CHEN Zhiqiang，JIA Zhuo，ZHANG Xu （Department of Urology，The First Medical Centre，Chinese PLA General Hospital，Beijing 100853，Chi

ABSTRACT：Prostatecancer is a prevalent malignant tumor of the male genitourinary system in China，with a persistently elevated incidencerate.Giventheinsidiousonset，propensityformetastasisinadvancedstages，andpoorefficacyof traditional treatments，new hormone therapies havegarnered increasing atention inrecent years.A numberof clinical studies have demonstrated thatsecond-generationandrogenreceptor inhibitors（SGARIs），includingenzalutamide，apalutamide， darolutamide，andrezvilutamide，can bebeneficial in diferent stagesof advancedprostatecancer.Furthermore，theirearly application has been shown todelay disease progression while maintaining acontroled safety profile.At present，SGARIs have increasinglybecometheprimarytherapeuticagentsforadvancedprostatecancerinvariousstages.Thisarticlereviews the clinical research progressof SGARIs inrecent years，with theaimof ofering valuable clinical reference for clinicians.

KEY WORDS：advanced prostate cancer;novel hormone therapy；second-generation androgen receptor inhibitors；androger deprivation therapy

摘要：前列腺癌是我国常见的男性泌尿生殖系统恶性肿瘤，发病率较高。（剩余14643字）